Physician profile
Vicky Savas
NPI 1851348494
$15,226.53
in general payments reported to CMS, 2019-2025
35 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $3,217 · 2021: $1,901 · 2022: $1,914 · 2023: $2,463 · 2024: $2,245 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,666 · Consulting Fee: $15.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,666.46 |
| Consulting Fee | $15.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $2,080.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,517.63 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,465.95 | 2019-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $1,182.37 | 2022-2025 | Cds - Mct/Cem Monitoring, Bodyguardian, Latitude Communicator Power Supply |
| Astrazeneca Pharmaceuticals LP | $1,155.62 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Pfizer INC. | $1,150.74 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $1,102.30 | 2021-2025 | Onpattro, Amvuttra |
| Amgen INC. | $933.75 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $594.63 | 2020-2025 | |
| Medtronic Vascular, INC. | $521.22 | 2019-2020 | |
| Esperion Therapeutics, INC. | $423.20 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $375.83 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.30 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $334.31 | 2021-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $294.83 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $242.32 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Actelion Pharmaceuticals US, INC. | $189.77 | 2021-2025 | Opsumit, Uptravi |
| Bardy Diagnostics, INC. | $174.46 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $161.08 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $141.28 | 2019-2022 | |
| Bridgebio Pharma, INC. | $123.84 | 2025 | Attruby |
| Lundbeck LLC | $120.38 | 2019-2021 | |
| Medtronic, INC. | $103.76 | 2021-2024 | Mycarelink |
| Astellas Pharma US INC | $89.99 | 2022 | |
| Baxter Healthcare | $76.08 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Heartflow, INC. | $55.37 | 2023-2025 | Ffrct |
| Kestra Medical Technology Services, INC. | $41.96 | 2024 | Assure Wcd |
| Vivaquant INC, Dba Rhythm Express | $35.65 | 2024 | Rhythm Express |
| Sobi, INC | $33.46 | 2023 | |
| Amryt Pharma Holdings LTD | $32.68 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $27.98 | 2023 | Arcalyst |
| Abiomed | $23.60 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $22.59 | 2022 | |
| Cordis US Corp. | $19.45 | 2025 | Mynx Control Venous |
| Irhythm Technologies, INC. | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Savas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.